10-Q: Azitra Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Azitra Inc., a clinical-stage biopharmaceutical company, reported its financial results for the second quarter ended June 30, 2024, highlighting ongoing clinical trial progress and strategic partnerships.

Summary

• Azitra Inc. is a biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products.
• The company reported a net loss of $2.63 million for the three months ended June 30, 2024, and a net loss of $5.56 million for the six months ended June 30, 2024.
• Service revenue from a related party was $7,500 for both the three and six months ended June 30, 2024, compared to $172,000 and $285,300 for the same periods in 2023, respectively.
• General and administrative expenses increased to $1.55 million for the three months and $3.04 million for the six months ended June 30, 2024, due to costs associated with being a public company.
• Research and development expenses were $1.12 million for the three months and $2.59 million for the six months ended June 30, 2024, reflecting increased clinical trial activity.
• As of June 30, 2024, the company had total assets of $3.88 million and a working capital deficit of $0.4 million.
• The company completed a follow-on public offering in July 2024, raising approximately $10 million in gross proceeds.
• Management has expressed substantial doubt about the company's ability to continue as a going concern due to ongoing losses and the need for additional capital.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with positive clinical trial progress but significant financial challenges, including a going concern warning. The sentiment is negative due to the financial risks and uncertainties.

Positives

• The company has commenced operating activities for its Phase 1b clinical trial of ATR-12.
• The company is planning to submit an IND for ATR-04 in the third quarter of 2024.
• The company completed a follow-on public offering in July 2024, raising approximately $10 million in gross proceeds.
• The company has a proprietary platform and microbial library for developing therapeutic products for precision dermatology.
• The company has established partnerships with leading academic institutions.

Negatives

• The company experienced a significant decrease in service revenue from a related party.
• The company's general and administrative expenses have increased substantially.
• The company has a working capital deficit of approximately $0.4 million.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• The company has incurred significant net losses for the reported periods.

Risks

• The company is subject to the risk of failure to secure additional funding to execute its business plan.
• The company is dependent on key personnel and third-party manufacturers.
• The company faces risks related to the protection of proprietary technology and compliance with regulatory requirements.
• The company's ability to convert joint development work with Bayer into a commercial license is uncertain.
• The company's cash on hand may not be sufficient to cover its proposed plan of operations over the next twelve months.

Future Outlook

The company expects research and development expenses to increase significantly due to planned clinical trial activity and continued development of product candidates. Management believes that the company's cash on-hand may not be sufficient to cover its proposed plan of operations over the next twelve months and intends to seek additional funding through various financing sources.

Management Comments

• Management has identified conditions and events that create substantial doubt about the company's ability to continue as a going concern.
• Management plans to continue to raise funds through equity and debt financing to fund operating and working capital needs.
• Management believes that the company has established a unique position in advancing the development of biologics for precision dermatology.

Industry Context

The company is operating in the competitive biopharmaceutical industry, focusing on precision dermatology. The company's approach of using engineered proteins and live biotherapeutic products is innovative, but it faces challenges common to early-stage companies, including funding, regulatory hurdles, and competition from established players.

Comparison to Industry Standards

• Azitra's financial results are typical of an early-stage clinical biopharmaceutical company with limited revenue and significant research and development expenses.
• The company's reliance on external funding is common in the biotech industry, but the current working capital deficit and going concern warning are concerning.
• Compared to companies like Amgen or Regeneron, which have established revenue streams, Azitra is in a much earlier stage of development and faces higher risks.
• The company's focus on genetically engineered bacteria for dermatology is a niche area, and there are few direct comparables, making benchmarking difficult.
• The company's partnerships with academic institutions are a common strategy for early-stage biotech companies to leverage external expertise and resources.

Management Changes

Corporate Governance

Related Party Transactions

• The company had service revenue from a related party of $7,500 for both the three and six months ended June 30, 2024.
• In September 2022, the company entered into a convertible promissory note totaling $4,350,000, of which $4,000,000 was attributable to an entity who was also an investor in the company's Series A, A-1, and B Preferred Stock financing.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and the potential for loss of investment due to the company's going concern status.
• Employees may be impacted by potential cost-cutting measures or restructuring if the company faces financial difficulties.
• Customers and partners may be affected by delays in product development or commercialization due to funding constraints.
• Creditors face the risk of non-payment if the company is unable to secure additional funding.

Next Steps

• The company expects to report initial safety results of its Phase 1b clinical trial for ATR-12 by year-end 2024.
• The company plans to submit an IND for a Phase 1b clinical trial of ATR-04 in the third quarter of 2024.
• The company is planning to perform lead optimization and IND-enabling studies for ATR-01 in 2024, targeting an IND filing in the second half of 2025.
• The company intends to seek additional funding through various financing sources.

Key Dates

Keywords

biopharmaceutical, dermatology, engineered proteins, live biotherapeutic products, clinical trials, Netherton syndrome, EGFRi, ichthyosis vulgaris, microbial library, genetic engineering, public offering, going concern